Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Gains from Sales and Divestitures (2020 - 2023)

Serina Therapeutics' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $3000.0 for Q3 2023.

  • For Q3 2023, Gains from Sales and Divestitures fell 70.0% year-over-year to $3000.0; the TTM value through Sep 2023 reached $3000.0, down 70.0%, while the annual FY2022 figure was $13000.0, 8.33% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2023 was $3000.0 at Serina Therapeutics, roughly flat from $3000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $22000.0 in Q4 2020 and bottomed at $3000.0 in Q1 2020.
  • The 4-year median for Gains from Sales and Divestitures is $7000.0 (2022), against an average of $9181.8.
  • The largest annual shift saw Gains from Sales and Divestitures increased 16.67% in 2022 before it plummeted 70.0% in 2023.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $22000.0 in 2020, then tumbled by 45.45% to $12000.0 in 2021, then increased by 8.33% to $13000.0 in 2022, then plummeted by 76.92% to $3000.0 in 2023.
  • Per Business Quant, the three most recent readings for SER's Gains from Sales and Divestitures are $3000.0 (Q3 2023), $3000.0 (Q2 2023), and $3000.0 (Q1 2023).